Early dual treatment helps late-diagnosed PAH patients catch up

Robyn Kalda
Jul 21, 2025
1 min read

Early use of dual therapy helps newly-diagnosed pulmonary arterial hypertension patients do as well as patients six months past diagnosis.

Newly-diagnosed patients' health is often worse than patients who have been treated for six months or more. However, US registry data showed that newly-diagnosed patients given macitentan and tadalafil had, after a year, similar survival and hospitalization rates to prevalent patients. Starting dual therapy soon after diagnosis may have some benefit.

Read the Advances in Therapy article

Recent Posts

Screening for PH in ILD

This study looked at how to better detect pulmonary hypertension (PH) in people with interstitial lung disease (ILD), since PH often makes breathing problems, quality of life, and survival worse. Rese

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

Comments